How we work
We break down the traditional silos across the life-science industry and share information to increase accountability and facilitate progress.
IFPMA serves as the secretariat of the AMR Industry Alliance with the responsibility of implementing the activities endorsed by the Board. The Board is the governing body of the AMR Industry Alliance. It is responsible for the planning and oversight of AMR Industry Alliance’s activities.
A biotechnology entrepreneur and immunologist by training, Deborah has over two decades of experience in anti-infective drug discovery research and development. Deborah studied at University College London and then worked in postdoctoral positions in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen (to the Rowett Research Institute, now part of the University of Aberdeen) where she founded NovaBiotics in 2004. The business has since become a leading global biotechnology business, developing a portfolio of first-in-class anti-infective therapies addressing the urgent, unmet need for safe and effective antimicrobials including Nylexa for COVID-19. NovaBiotics is on the front line of the fight against antimicrobial resistance (AMR).
Deborah is a Board member of the UK’s BioIndustry Association, a Director and founding member of the BEAM Alliance (Biotechs of Europe innovating in Anti-Microbial Resistance), was a member of the Scottish Life Sciences Industry Leadership Group and sit on the Boards of the Scottish Life Sciences Association and Opportunity North East Life Science/BioAberdeen. Deborah serves as Chairperson of the UK’s Medicines Discovery Catapult-Cystic fibrosis (CF) Trust’s working group on antimicrobials in CF and sits on the UK BioIndustry Association’s working group on AMR. Elected as a Fellow of the Royal Society of Edinburgh in 2018 and a Fellow of the Royal Society of Medicine. Named as one of the 20 women leaders in European biotech in 2019, one of the 30 top female leaders in UK Healthcare in 2018 and one of the 15 leading women European biotech in 2017. In 2020, Deborah was made OBE in the Queen’s Birthday Honours list, for services to biotechnology, industry and charity.
Eric is a chemist by training. He is currently heading the Medicinal Chemistry Group of Evotec ID Lyon while being the Evotec Innovate AMR portfolio leader. He worked for Sanofi and its predecessor companies (Rhône-Poulenc and Aventis) for almost 30 years before joining Evotec mid-2018. Eric has been working in the field of infectious diseases (antibacterial, anti-mycobacterials, anti-virals and anti-fungals) for more than 20 years. In the field of antibacterials, he has conducted or contributed to multiple research and preclinical development projects across numerous antibacterial targets and chemical series. This work led for instance to the clinical antibacterial candidates NXL-101 and NXL-103. Eric is particularly committed to the fight against AMR and, along these lines, he has contributed in recent years, as EFPIA co-coordinator of the IMI ENABLE consortium and as Project Lead for the GNA NOW consortium, to various European initiatives aiming at developing new classes of antibacterials active on the key drug-resistant Gram-negative pathogens.
Dr. Tenover is Vice President for Scientific Affairs at Cepheid, where he has worked since 2008. He also serves as Consulting Professor of Pathology at Stanford University School of Medicine, Adjunct Professor of Epidemiology in the Rollins School of Public Health at Emory University, and Consulting Professor of Biology at the University of Dayton. Prior to joining Cepheid, he served for 18 years at the Centers for Disease Control and Prevention (CDC) in Atlanta as Associate Director for Laboratory Science in the Division of Healthcare Quality Promotion, where he directed the antimicrobial susceptibility testing laboratories, and the staphylococcal, anaerobe, and nosocomial gram-negative organism identification laboratories. His research team discovered the KPC carbapenem resistance gene and several other key resistance determinants. He then became the Director of the Office of Antimicrobial Resistance for CDC. Dr Tenover was a member of the CLSI Antimicrobial Susceptibility Testing Subcommittee for 17 years, developing novel test methods for resistance detection and interpretive criteria for new antimicrobial agents. At Cepheid, in addition to working on strategies for new product development and innovation, his research team focuses on rapid detection of healthcare-associated infections and mechanisms of carbapenem resistance. He is a Diplomate of the American Board of Medical Microbiology and a Fellow of both the American Academy of Microbiology and the Infectious Disease Society of America. He has authored over 330 peer-reviewed journal articles and has written or edited 11 books on microbiology and molecular diagnostics.
Dr. Larsen is a globally recognized leader in the area of public health preparedness with more than 20 years’ experience. As Vice President, Strategic Portfolio Development at Venatorx Pharmaceuticals, Dr. Larsen is responsible for identifying new growth opportunities and translating the company’s rich internal programs toward strategic public and private partnerships.
Previously, Dr. Larsen served as Director of the Division of CBRN Medical Countermeasures within the Biomedical Advanced Research Development Authority (BARDA). In that role, he oversaw a $2.8B fund for the late-stage development and procurement of medical products for use during public health emergencies and a $530M annual advanced research and development fund. Additionally, Dr. Larsen supported the development and regulatory approval for a novel smallpox antiviral drug, two novel antibiotics, and a cytokine therapy to treat the hematopoietic effects of acute radiation exposure. He also led the establishment of Project Bioshield programs to develop vaccine and therapeutics to safe guard the American public from future Ebola virus outbreaks. Dr. Larsen was the lead for BARDA’s work on combating antibiotic resistant bacteria and was an executive member and founder of CARB-X, a novel $450M public private partnership focused on promoting innovation in antibacterial drug development. Dr. Larsen has also been involved in discussing potential reforms to the economic incentive structures for antibacterial drug development.
Previously, Dr. Larsen served as Chief of the Broad Spectrum Antimicrobials program at BARDA. In that role, Dr. Larsen oversaw a portfolio of approximately $1.2B in programs that supported the development of novel antibacterial and antiviral drugs. Dr. Larsen also served as the BARDA representative on the U.S. Transatlantic Task Force on Antimicrobial Resistance, and as a Senior Science and Technology Manager at the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBDP) within the Defense Threat Reduction Agency (DTRA).
Dr. Larsen was an American Association for the Advancement of Science (AAAS) fellow at the Department of Homeland Security. Additionally, he was a 2005 National Academy of Science Christine Mirzayan fellow with the Board of Life Sciences. Dr. Larsen received his Ph.D. in Microbiology from the Uniformed Services University of the Health Sciences and his B.A. with honors from the University of Kansas.
Head of Health Security and Infectious Disease Policy and Advocacy
John Billington is Head of Health Security and Infectious Disease Policy and Advocacy in the global corporate government affairs department of GSK. In this role, he is responsible for the company’s policy and advocacy strategy for infectious diseases at the enterprise level, with a focus on pandemic preparedness and antimicrobial resistance (AMR). Prior to this role, John was director of science policy for the global vaccines business and director for U.S. vaccines policy before that. Before joining GSK, John was director of health policy at the Infectious Diseases Society of America (IDSA). At IDSA, John served as lead subject matter expert on vaccines, antibiotics, and medical countermeasures policy. He also launched and coordinated the U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR), a national stakeholder partnership to advance U.S. and global policies and practices in response to AMR. Earlier in his career, John was a manager in the health reform practice at Avalere Health, a health policy advisory firm. He was also a legislative fellow for health policy in the office of U.S. Senator Sherrod Brown of Ohio. John received his Juris Doctor and Masters of Public Health from the Ohio State University in Columbus, Ohio. He received his undergraduate degree from Colgate University in Hamilton, New York.
Kirsten Nyland has more than 30 years of experience within the pharmaceutical industry in various managerial positions in sales and marketing, strategic planning, research and development, governmental affairs, sustainability and CSR on national, regional and global level.
Today Kirsten is Vice President at Fresenius Kabi leading Environmental & Occupational Management throughout the global organization. In this position, she focuses on enhancing Environment, Sustainability, Health and Safety as well as Occupational Health and Safety to continuously fulfill increasing expectations from internal and external stakeholders.
Kristine Peers is General Counsel at the European Federation of Pharmaceutical Industries and Associations (EFPIA) since September 2017. Her role includes responsibility for EFPIA’s policy solutions to address antimicrobial resistance (AMR).
Through its direct membership of 36 national associations, 39 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.
Kristine builds on a career combining legal expertise with public policy and government relations. She has worked in various legal and corporate affairs functions at Belgian, European and global level with GlaxoSmithKline and Pfizer. Prior to joining the pharmaceutical industry, Kristine practiced at
the Belgian Bar. She graduated in law from Leuven University, Belgium, and obtained a postgraduate qualification in European Law at the European University Centre in Nancy, France, where she was also visiting lecturer teaching European regulations of medicinal products to health professionals. Throughout her career she had several legal, business and leadership training including at INSEAD and NYU Stern. She is co-founder of the Brussels Pharma Law Group.
Marc Gitzinger is Chief Executive Officer and co-founder of BioVersys. He has over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset early clinical stage company. Some of these assets will address significant unmet medical needs in infectious conditions such as tuberculosis and hospital acquired Acinetobacter infections. He has raised over $30 mio in equity financing and secured over $20 mio in non-dilutive funding. He has also established several important partnerships with a Big Pharma and other development organizations. Dr. Gitzinger is a multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. He is also vice-president of the board of the BEAM Alliance, a European association representing over 60 European and international SMEs active in antimicrobial research and development. Dr. Gitzinger is a young thought leader in the field of antimicrobial research and development. He is passionate about next generation antimicrobial therapies and leads a highly motivated team striving to bring life-saving antimicrobial therapies to patients in need. He is also co-author on several high ranked scientific publications and patents in the field.
Dr Masoud Dara is a physician and public health professional from Belgium with more than 25 years of experience in designing, implementing and evaluating health programs with a focus on infectious diseases in about forty countries across four continents.
Since November 2021, he functions as the Director of Global Health and Alliances at Otsuka Novel Products Group GmbH.
From October 2020 to October 2021, Dr Dara served as the Special Representative of the WHO Regional Director to Belarus, providing strategic guidance and policy dialogue and leading the WHO Country Office activities in the country. From October 2016 to October 2020, he coordinated the WHO Regional Office for Europe’s Communicable Diseases Department and led the WHO/Europe’s Joint Tuberculosis, HIV and viral hepatitis program. Before that, Dr Dara functioned as the WHO Senior Advisor to the European Union for two consecutive years. He led the WHO/Europe’s TB and MDR-TB program between 2010 and 2014. From 2001 to 2010, he served as a Senior Consultant of the Royal Netherlands Tuberculosis Association (KNCV) and functioned as a WHO Medical Officer in Moscow. In the beginning of his international career, Dr Dara worked as a medical doctor and Project Coordinator of Médecins Sans Frontières in Central Asia and as the Head of Belgian Red Cross in Kosovo between 1998 and 2001.
Dr Dara has authored more than 60 publications in peer-reviewed journals and several WHO guidelines. He has been a chair and member of various scientific working groups such as TB Control in Prisons of the International Union Against Tuberculosis and Lung Diseases. Furthermore, in various periods, he served an Associate Editor of International Journal of Tuberculosis and Lung Diseases, a member of the Editorial Board of Eurosurveillance and a member of the Editorial Board of International Journal of Environmental Research and Public Health.
He is fluent in Persian, English, French, Dutch and Russian.
Sarah McGill is Senior Director and Head Global Access Product Strategy for Roche. Sarah joined Roche in 2006 and has held a variety of marketing and market access leadership positions across the pharmaceutical division. She is responsible for global access strategies across the Roche portfolio including support for lifecycle decisions, regulatory and HTA approvals, pricing, and reimbursement. Sarah’s team leads Roche’s policy engagement on AMR via IFPMA and EFPIA. Roche’s commitment to combat AMR and achieve a new Platinum Age for antibiotics R&D is underpinned by substantial investment in the discovery and development of novel antibiotics and the development of diagnostic assays to rapidly identify the type of drug-resistance bacteria responsible for infection. Roche is proud to join together with industry partners to support AMR Action Fund – a collective venture organized by IFPMA that will contribute more than $1 billion towards novel antibiotic development and support advocacy for a robust and sustainable pipeline of new antibiotics to fight drug-resistant infections.
Susan Van Meter is Executive Director of AdvaMedDx. AdvaMedDx represents over 70 manufacturers of innovative in vitro diagnostics (IVD) tests, point-of-care (POC) and laboratory instruments and other technologies, seeking to advance policy to promote innovation and expand access to quality testing. Based in Washington, D.C., AdvaMedDx is the only advocacy organization exclusively addressing policy issues facing diagnostics manufacturers in the U.S. and around the world.
AdvaMedDx operates as a division of AdvaMed, the Advanced Medical Technology Association. AdvaMed is the world’s largest medical technology association with over 400 member companies that develop medical devices, diagnostic tools, and health information systems.
Given the critical role quality diagnostic tests serve in the fight against drug-resistant infection, AdvaMedDx has led the development of Diagnostic Stewardship recommendations. These recommendations provide practical policy guidance to clinicians on leveraging diagnostic tests to improve informed prescribing of antibiotics as part of any meaningful effort against Antimicrobial Resistance (AMR).
Prior to joining AdvaMedDx in 2018, Ms. Van Meter served as senior vice president at the Healthcare Association of New York State (HANYS) and focused on hospital and health system policy, payment, quality, and health information technology priorities. She also previously served in the U.S. Department of Health and Human Services, Centers for Medicare and Medicare Services, Office of Legislation. Ms. Van Meter has an undergraduate and a graduate degree from Villanova University and Boston University, respectively.
Dr. Tanya Gottlieb serves as Vice President of Scientific Affairs at MeMed, a company pioneering host response technologies. She joined in 2014 and leads MeMed’s international collaborations and non-dilutive funding projects, focused on improving patient management and antibiotic stewardship via tools that support decision making on appropriate use. Before joining MeMed, Dr. Gottlieb was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative start-up developing a universal flu vaccine, where she established relationships with the National Institute of Health (US) and European Commission. Dr. Gottlieb conducted her postdoctoral research at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. She holds a BA in Natural Sciences and a PhD from Cambridge University in the UK and an MBA from the Technion in Israel.
Thomas B. Cueni is Director General of IFPMA, the global association of pharmaceutical research companies, based in Geneva. Thomas Cueni represents the innovative biopharmaceutical industry on the ACT Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, a unique global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. Thomas Cueni has been instrumental in creating the AMR Action Fund and he is Chair of the Board of the cross-sectoral AMR Industry Alliance. Prior to joining IFPMA he was Secretary General of Interpharma (Switzerland) and was a member of the Board and Chair of the European Federation of Pharmaceutical Industries and Associations. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”. He served as a Swiss diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).
Regulatory and policy expert, lawyer by training, Sabrina joined Medicines for Europe in 2018 and currently leads the Manufacturing and Supply Chain Committee, AMR and Environmental working groups. Prior joining the pharmaceutical sector, she also worked in public organisations like the European Commission and Italian Ministry of Justice. Sabrina holds an LLM in International and European law from the Vrije Brussels University.
Gareth Morgan is Senior Vice President and Head of Global Portfolio Management for Shionogi. In addition to leading the Portfolio Management team, Gareth is responsible for providing strategic and policy direction related to anti-infective agents, and frequently represents Shionogi on anti-infective related government affairs and policy assignments, particularly those associated with the growing threat of antimicrobial resistance. Gareth has more than 25 years of experience with pharmaceutical and biotech companies, including BMS, Bayer, Genentech (now Roche) and Hoechst-Roussel (now Sanofi). He has led or provided functional and strategic oversight to development programs across multiple geographies and therapeutic areas.
Bruce Altevogt is a Vice President and Head External Medical Engagement within Pfizer Inc.’s Hospital Business Unit, which includes managing the industry leading AMR surveillance program, Atlas. Prior to this role he was a Senior Director of Science Policy and Science Advocacy within Global Policy and International Public Affairs. In this role Dr. Altevogt was responsible for managing policy issues in support of Pfizer’s research & development enterprise, vaccines and was lead for anti-microbial resistance policy. Prior to joining Pfizer Inc. Dr. Altevogt served as a senior program officer on the Board on Health Sciences Policy at the Institute of Medicine, where he led policy initiatives related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. Dr. Altevogt received a doctorate from Harvard University’s Program in Neuroscience and a B.A. from the University of Virginia, where he majored in Biology and minored in South Asian Studies. He is a published author of multiple scientific articles.
Paul Schaper, Executive Director, Global Public Policy, leads global policy efforts at MSD in Global Pharmaceuticals, which includes a broad range of therapeutic areas from diabetes to cardiovascular disease, neuroscience, reproductive health, and infectious disease, including hepatitis, HIV, and antibiotics/antifungals. From 2013 – 2017, he served as the Board Member for the Private Sector Constituency on board of the Global Fund for HIV, TB, and Malaria. He currently serves as the Private Sector Alternate Board Member. He earned his B.A. and master’s degrees in public health policy and business administration from Emory University and a master’s degree in clinical psychology from Georgia State University.
Adrian Thomas, M.D., is the Vice President, Global Programs Strategy & Evaluation with the Johnson & Johnson Global Public Health organization. Adrian has a special interest in the fields of public health, commercial and market access strategy, and pharmaceutical policy. He also held numerous roles in market access including Global Head Health Economics & Market Access Medical Devices. He was Global Head of Market Access for Janssen, the pharmaceutical companies of Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Manager and Chief Safety Office for Janssen. Prior to joining J&J, Adrian held roles in regional medical affairs, drug development and product management for Schering-Plough and Eli Lilly. He is a clinical pharmacologist and vascular physician with experience in clinical trials design and methodology. Adrian is a Fellow of the Royal Australasian College of Physicians and the College of Medical Administrator’s. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia. He is based in New Hope, Pennsylvania.
Yonina Fleischman holds the position of ESG Access to Medicines Lead at Teva Pharmaceuticals. In her role, she leads Teva Access, a key component of Teva’s ESG strategy, whose mission is to bring sustainable solutions that expand access to Teva’s broad portfolio of medicines to improve the health of patients in need throughout the world. Teva’s access strategic donation and social business programs are largely geared specifically toward vulnerable populations with unmet need in low and middle income countries, who experience financial affordability or physical access barriers. Prior to her role at Teva, Yonina has held positions at the Israeli Ministry of Health and at a number of Israeli non-governmental organizations, with a focus on access to care and health promotion. She has also worked extensively on health promotion within the Bedouin population and the asylum seeker community in Israel. An avid traveler, Yonina has spent considerable periods of time working in the field of public health with low income communities around the world, with an emphasis on women, children and other vulnerable populations. This has included health outreach in Ghana, empowerment programming in Nepal, and community development and health advocacy in post-earthquake Haiti. Originally from the US, Yonina is now based in Israel. She holds a Master’s in Public Health from the Hebrew University of Jerusalem and a Bachelor’s in International Studies from Brandeis University.
Dr. Boumediene Soufi is a biotechnologist by training, specializing in the field of microbial quantitative proteomics. He holds the position of Global Head Antimicrobial Resistance at Sandoz, the largest provider of generic antibiotic medicines globally. The program focuses on combatting this unprecedented global health threat in collaboration with multi-sectoral partners.
Boumediene joined Sandoz in 2015 and has held progressively senior positions focusing on sustainable efficiency, digital innovation, and leading the entire end-to end Sandoz anti-infectives portfolio pipeline ensuring that patients worldwide have access to the right medicine at the right time.
His passion and motivation for combatting AMR is rooted in his extensive scientific experience, particularly studying complex bacteria and their resistance mechanisms. He combines this with a strong commercial understanding of the pharmaceutical industry and the role of appropriate incentives in shaping effective public health policy. Boumediene firmly believes that a strong wide-ranging public-private collaboration effort focused on innovation, proper antibiotic use through strong stewardship efforts, robust surveillance processes, and improved access to quality affordable medicines are keys to winning the fight against AMR.
Charles Koon (“Chuck”), Head of Global Operations Auditing, Clinical Quality and Regulatory Intelligence for Viatris, has over 29 years of experience in the pharmaceutical industry. He has served in various capacities within site and global quality functions and played a fundamental role in transitioning Legacy Mylan from a U.S.-focused company to a global organization. Since Mylan’s transition to Viatris, Chuck has lead his team to achieve the goal of delivering increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance, along with striving towards empowering people worldwide to live healthier at every stage of life.
Beginning his career in 1992 as a Quality Control Chemist with Mylan Pharmaceuticals, he has held numerous managerial roles of increasing responsibility over the years throughout Quality Operations. As Mylan progressed into a global organization, Chuck was integral in the vision and development of Global Quality including operational, compliance, and systems development functions. This included development of the organizational structure, mapping of key systems and processes, and implementation and oversight of globally harmonized systems such as complaints management, internal and external cGMP auditing, change control, and investigations.
In 2016, Chuck was appointed as Head of Global Operations Auditing, Clinical Quality and Regulatory Intelligence for Viatris. Chuck had previously led these departments for Legacy Mylan since inception. For Viatris, he will continue to manage an internationally-based team with specialties in GMP, GCP, GLP, GPvP, GDP, EHS, and Regulatory Affairs compliance with a focus on standardized, coordinated, and objective auditing services designed to evaluate Viatris’ operations related to compliance with regulations, internal policies, best practices, and industry standards.
In the area of Regulatory Intelligence, Chuck oversees the development and delivery of consistent and standardized adult learning on global policies, corporate training initiatives, industry trends identified via regulatory intelligence, and quality culture.
In addition to his current responsibilities, Chuck collaborates with the Global Social Responsibility team to ensure that the most accurate data is captured and reflected in the annual GSR submission. Also, he has participated in the FDA Generic Drug User Fee (GDUFA) development process, been a key member in supporting major due diligence projects, and continues to be involved in industry-leading efforts to establish one global high quality standard for all Viatris products, raise quality standards for all drug manufacturers globally, and expand the world’s access to affordable, quality medicines for patients worldwide
He holds both Bachelor of Science and Master of Science degrees from West Virginia University.
Alba leads the Sustainable Antibiotics program at Centrient Pharmaceuticals where she works on sustainability and health issues such as antimicrobial resistance and environment, access to life-saving antibiotics and appropriate use. She represents Centrient Pharmaceuticals in industry platforms and within multi-stakeholder initiatives. Internally, she drives sustainability throughout the organization by coordinating local sustainability champions and sharing the impact of the global effort across the company. Alba has a Master’s degree in Strategic Management from the Rotterdam School of Management.
Jean-Louis is Vice President, Public and Government Affairs – AMR at bioMérieux since 1 October 2019. He joined the company 35 years ago holding roles of increasing responsibility, most recently as Vice President Global Marketing in Microbiology (2007-2011) and Vice President Northern Europe (2011-2019) which allowed him to accumulate rich experience in the field of in vitro diagnostics. Jean-Louis graduated from the Business School of the Conservatoire National Des Arts et Métiers in Paris and received his Master degree in Biology from the University of Paris.
Adam Zerda is Director, Antimicrobial Resistance (AMR) Strategy and Development for BD. BD efforts to help combat AMR include a broad portfolio of solutions strategically positioned to play an active role in addressing this threat. In his role, Adam is responsible for developing and executing BD’s strategy for combatting the challenge of AMR globally by working to help build awareness of AMR, engage external stakeholders in policy and advocacy efforts around AMR, and develop training and process improvement programs, focusing specifically on infection prevention and antimicrobial stewardship. In leading BD’s AMR efforts, Adam is accountable for developing and implementing organization-wide, cross-functional alignment around this issue by working collaboratively with businesses, regions and functions. Prior to this role, Adam has held positions in business development, strategic innovation and research and development at BD. He joined the company in 2007. Prior to BD, Adam held roles in product development for GE Plastics. Adam has a Ph.D. in Polymer Science and Engineering (2002) from the University of Massachusetts in Amherst and a B.S. in Chemistry (1998) from TCU. He is based in North Carolina where he additionally sits on the board of North Carolina BIO.
Anand is co-founder and CEO of Bugworks, an Indo-USA pharma start-up, one of a handful of companies working on developing novel classes of antibiotics to tackle the global problem posed by multi-drug resistant bacterial superbugs. The company’s lead asset, entering clinical development during Q2 2021, is a novel dual target inhibitor with excellent potency against the entire list of WHO critical, high and medium threat pathogens. The company has won many national and international innovation awards including the Best start-up in India (2015), Economic Times Top Innovator award (2017), first company outside North America and Europe to win the coveted CARB-X grant, and has been featured in the CB-InSights 2019 list of top 36 global start-ups. Bugworks has prominently featured on leading global platforms including the BBC, Wellcome Trust, UNCTAD, CDC and Forbes.
Anand was previously co-founder and Managing Director, Cellworks, a company specializing in personalized oncotherapy, using mathematical modelling frameworks. He is also the Co-founder of the India semiconductor association (IESA), Vice-President & Member of Executive committee of India Biotech association (ABLE), member of Eta-Kappa-Nu and Tau-Beta-Pi International Engineering honours societies, member of the board of AMR Industry Alliance and member of the India advisory council of GARDP.
Emily Wheeler is Director of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO). Ms. Wheeler is responsible for working with member companies engaged in antimicrobial research, development, and commercialization, and leads BIO’s antimicrobial resistance (AMR) legislative and regulatory policy efforts. She is also the Director of the Working to Fight AMR public awareness campaign. Ms. Wheeler serves on the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) and is a member of the Stakeholder Group for the Global AMR R&D Hub. She represents the biotech sector as Board member on the AMR Industry Alliance (AMRIA) and is co-Chair of AMRIA’s Research and Science Working Group. Prior to joining BIO, Ms. Wheeler held a position as Associate Director at The Conafay Group, a life-sciences government relations firm that serves as coalition manager and Washington Counsel for the Antimicrobials Working Group (AWG). In this role Ms. Wheeler led AMR policy efforts for a coalition of small and mid-sized antimicrobials companies, and engaged with stakeholders representing health care providers, patients, public health, scientists, and industry. Ms. Wheeler has gained experience in health care policy and provision both domestically and internationally. She conducted fieldwork in Senegal, Rwanda and the Philippines focused on health care in several capacities: maternal and child health, nutrition, emergency relief for refugee populations, and monitoring and evaluation for a variety of programs. Additionally, she developed skills in project management and overall programmatic analysis through collaboration with local and international health and development experts. Ms. Wheeler is a Presidential Academic Scholar from the George Washington University and earned a bachelor’s degree in International Affairs with dual concentrations in Global Public Health and International Development.